Literature DB >> 14760314

Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT.

Eli V Gelfand1, Christopher P Cannon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14760314     DOI： 10.1016/j.ahj.2003.09.011

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  4 in total

1.  Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial.

Authors:  Christian M Jespersen; Bodil Als-Nielsen; Morten Damgaard; Jørgen Fischer Hansen; Stig Hansen; Olav H Helø; Per Hildebrandt; Jørgen Hilden; Gorm B Jensen; Jens Kastrup; Hans Jørn Kolmos; Erik Kjøller; Inga Lind; Henrik Nielsen; Lars Petersen; Christian Gluud
Journal:  BMJ       Date:  2005-12-08

2.  Antibiotics active against Chlamydia do not reduce the risk of myocardial infarction.

Authors:  Lars Bjerrum; Morten Andersen; Jesper Hallas
Journal:  Eur J Clin Pharmacol       Date:  2005-12-06       Impact factor: 2.953

Review 3.  The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease.

Authors:  Rima Mohsen Chakaroun; Lisa M Olsson; Fredrik Bäckhed
Journal:  Nat Rev Cardiol       Date:  2022-10-14       Impact factor: 49.421

Review 4.  Chlamydia pneumoniae and atherosclerosis: from Koch postulates to clinical trials.

Authors:  Catherine Liu; David D Waters
Journal:  Prog Cardiovasc Dis       Date:  2005 Jan-Feb       Impact factor: 8.194
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.